Background. AASLD/IDSA guidelines recommend 12 weeks of ledipasvir/ sofosbuvir for HCV genotype 1 infection treatment. HCV viral load (VL) is measured at baseline, week 4 of treatment, and at end of treatment (EOT). The aim of this study is to describe HCV/HIV patients who had post EOT viremia that did not correlate with treatment failure.
Methods. We reviewed data of patients with HCV/HIV co-infections treated with ledipasvir/sofosbuvir and post EOT viremia. Viral load was detected using Roche Second-Generation Cobas AmpliPrep/Cobas TaqMan which has high sensitivity and specificity with no reported cross-reactivity.
Results. Over the course of two years, we treated a total of 112 HCV/HIV co-infected patients. Four patients had EOT viremia (3.5%). During post-EOT HCV VL monitoring single episodes of HCV viremia (157-4511 IU/mL) were detected at 4-14 weeks post-EOT. All occurrences were preceded and followed by at least one undetectable HCV VL.
All patients reported excellent adherence to HCV therapy (pill count and patient report) except for one patient who missed two weeks of therapy. All patients had absolute CD4+ cell count >250 cells/mm3. Methods. At our clinic, a quality improvement project incorporating treatment algorithms targeting HCV/HIV was established for providers to guide HCV therapy.
Results. From January 1, 2014 to April 30, 2017, a total of 71 (12 F 59 M; 35 AA/1 H/35 W; Risk: 38 IVDU/31 MSM) HCV/HIV co-infections were identified (GT1: 57; GT3: 6; GT4: 1) with median age of 52 years (range: 21-73). Among them, 21 had fibrosure scores ≥ 3 and 22 <2. Out of 43 patients, 38 completed DAA (test of cure: 34) and 5 are currently on therapy. Lengths of treatment were 8 weeks (4), 12 weeks (30), 16 weeks (1) and 24 weeks (3). All patients had undetectable HCV viral loads at end of treatment (EOT) and test of cure (TOC) visits. Owing to our clinic staff members' persistent efforts, 5 patients remained adherent to therapy despite having medical events requiring inpatient admission. One patient skipped 7 days of therapy (D22-D28) but still achieved undetectable levels at the EOT and TOC.
Among those who had not received DAA (28), 5 died (AIDS:1, Malignancy:2, ESRD:2, Liver disease:1), 3 patients cleared the HCV virus without DAA; 4 Incarcerated; and 3 lost to care. Other barriers to therapy included Fibrosure <2 (preceding 2/1/2017), metastatic cancer, noncompliance and neuropsychiatric illness.
Conclusion. With DAAs, HCV co-infection rate at our PHC has decreased from 8% to 1.5%, anticipating further decrease to 0.5%. In our cohort, there were four HCV/HIV with GT1a were successfully treated with 8 weeks' course. This is not currently endorsed by the IDSA/AASLD guidelines for the co-infected population, however. Appropriate DAA HCV/HIV therapy coupled with intensive counseling and monitoring can possibly achieve 100% cure rate and elimination of HCV infection in HIV.
Disclosures patients are treated for HCV infection. This study aims to describe barriers to hepatitis C treatment in HIV/HCV co-infected patients.
Methods. We performed a retrospective observational study of HIV/HCV co-infected patients seen at an urban HIV clinic in the year of 2016 at Drexel University, Philadelphia, PA. We compared patients who were treated for HCV infection vs. those who were untreated. We described demographics and barriers-to-care associated with untreated HCV infection.
Results. Among 1322 patients seen, 112 patients had chronic HCV infection. The median age was 54 (IQR: 48-58) years old and two-thirds (78 (67.8%)) were AfricanAmerican. Median CD4 counts were 515 (354-750), 85% had controlled viremia (VL < 200 copies) and 43 (44.3%) had fibrosis scores above F3. Sixty were treated for chronic HCV. Among the 55 untreated patients, 20 (36.4%) were in the process of evaluation, 11 (20%) had uncontrolled HIV viremia (HIV viral load >200 copies) and 9 (16.4%) were actively using illicit substances. In HCV treated vs. untreated patients, it was more common to have an undetectable viral load (60% vs. 40%); CD 4 count > 200 (58% vs. 42%); and absence of cocaine abuse (58% vs. 42%). Patients who completed HCV treatment had a higher rate of HCC screening (62% vs 33%, P = 0.005).
Conclusion. Despite the availability of effective DAA therapy, only one half of co-infected patients were treated for HCV. The significant barriers in the delay of HCV treatment were uncontrolled HIV viremia and substance abuse. To overcome these barriers, we suggest: (1) providing support and resources to help patients cease cocaine use, (2) encourage frequent follow up with patients to achieve HIV suppression. This will improve access to treatment, decrease mortality, and improve the quality of life for this patient group.
Disclosures Methods. We performed a retrospective chart review from 2014 to 2016 of patients with HCV/HIV coinfection who received ledipasvir/sofosbuvir in a freestanding HIV clinic. Demographic data collected includes: HCV genotype (Gt), Fib-4 score, length of therapy (LOT), HIV viral load (VL), CD4+ cell count, antiretroviral therapy (ART), HCV RNA levels at baseline, 4 weeks, 8 weeks, end of therapy (EOT), and SVR at week 12 post-treatment. Statistical analysis was performed using Stata version 14 (STATA Corp., Texas, USA).
Results. A total of 94 patients were included. The mean age was 54 years-old, 78% were male. Most patients (95%) had Gt 1 HCV infection (84% 1A, 11% 1B and 1% mixed), 4% Gt 4, and one patient had Gt 6; 24% of patients had compensated cirrhosis.
Median LOT was 12 weeks. 95% of patients received 12 weeks, 4% 24 weeks, and 1% received 16 weeks of therapy. Most patients had undetectable HIV VL (77% with <20 copies/mL), while 23% had HIV VL range from 20 to 1,430 copies/mL. The mean CD4+ count was 639 cells/microliters (95% CI 567-711). The most commonly used ARTs were efavirenz/emtricitabine/tenofovir (21%), followed by abacavir/dolutegravir/lamivudine (15%). SVR12 was achieved in 99% (93/94) of patients (100% in HCV treatment experienced). Of those patients, 86/91 achieved HCV VL <15 at week 4 and 80/82 at EOT. The mean Fib-4 score at start of therapy was 2.33 with post-therapy of 1.35. One patient (Gt 1A, F4, on FTC/TDF/RAL) failed therapy secondary to NS5a mutation (L31M/V) and was retreated with sofosubuvir/simeprevir for 12 weeks achieving SVR 12. Interestingly, 4 patients had undetectable HCV VL at EOT with post-EOT HCV viremia (157-4511 IU/mL) that resolved on its own on repeated testing.
Conclusion. Our HCV real-life experience with ledipasvir/sofosbuvir at a freestanding HIV clinic confirms the efficacy and safety reported in randomized clinical trials. NS5A mutation led to treatment failure in this heterogeneous group of patients.
Disclosures. Saturday, October 7, 2017: 12:30 PM Background. Societal and economic burdens of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) continue to grow. The CDC recommends a one-time HCV screen for individuals in the Baby Boomer population (those born between 1945 and 1965) and a one-time HIV screen for all individuals between ages 13-64, with more frequent screening for both conditions based on individual risk factors.
Methods. A system-wide electronic medical record alert prompting HCV screening was implemented in May 2016 targeting the Baby Boomer population. In addition to the system alert, an educational program detailing disease epidemiology, screening recommendations, and algorithms to guide screening efforts was developed by a quality improvement team to increase HCV and HIV screening and linkage to care for positive patients. Carolinas HealthCare System (CHS) is a nonprofit, vertically integrated healthcare system with approximately 12 million patient encounters per year. Twelve primary care practices, including 5 safety-net practices serving predominantly Medicaid and uninsured patients, with total of 43,000 patients born between 1945 and 1965 were selected for the educational intervention.
Results. Prior to the system-wide HCV alert, from May-December 2015, 2430 patients were screened for Hepatitis C; one year later post-HCV alert, from MayDecember 2016, 8872 patients were screened, resulting in a 350% increase in screening. Chi-squared analysis comparing the percentage of patients tested between the two-time periods was significantly different (P = 0.001). For the educational intervention initiated in November 2016: average patient HCV testing over the 12 sites was 1480 per month before the intervention, and rose to 1713 per month post-education implementation (P < 0.001). Similarly, for HIV testing: average patient HIV testing was on average 493 per month increasing to 621 average per month after the educational program (P < 0.001) Conclusion. EMR modifications and provider education along with availability of connect to care partners within a large, integrated, healthcare system can significantly enhance screening and care for patients with HCV and HIV. Innovative interventions are needed to improve screening rates and link positive patients into care.
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